PM360
SEPTEMBER 21, 2023
They do not have biosimilar or generic competition available in the market. Additionally, highly competitive classes, such as rapid-acting insulin and immunologics are included on the selected drug list. After this period, CMS will begin to include physician-administered drugs covered under Part B in the program.
European Pharmaceutical Review
JULY 18, 2022
Nebido is also patented until March 2024 in the European Union and until May 2027 in the United States. The deal is expected to close by the end of 2022, subject to approval by the relevant competition authorities. The long-acting injectable treatment for testosterone deficiency has been commercially approved in more than 80 countries.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Clarivate
APRIL 18, 2024
The downsizing is not a total reversal of Walgreens’ aggressive primary-care clinic expansion plan (which in 2021 imagined 1,000 VillageMD clinics by 2027), but rather a reallocation of capital to increase VillageMD’s density in “high-opportunity” markets—i.e., those with high patient volumes.
Clarivate
OCTOBER 25, 2023
The dearth of cancer drugs (only blood cancer drug Imbruvica made this first list) stems from CMS only pursuing negotiations for Part D drugs in 2026 and 2027, then expanding to Part B drugs in 2028. exclusions exist for orphan drug designation and biosimilar competition ).
Medico Reach
DECEMBER 2, 2022
billion , and by 2027, it is expected to reach around an exciting amount of 115.1 from 2022 to 2027. Moreover, its services are spread through care organizations, hospitals, government agencies, pharmaceutical companies, and physicians. In 2022, the global clinical research market stands at $63.6 billion with a CAGR of 11.0%
Clarivate
APRIL 24, 2023
CVS then began affiliating with health systems across the country (like Cleveland Clinic ) for physician oversight of MinuteClinic’s staffed midlevel providers, just as Walgreens was rising as a formidable competitor in the convenient care space through its own walk-in clinics that it launched in fall 2006. Key acquisitions by U.S.
Pharmaceutical Technology
JANUARY 10, 2023
Type 2 diabetes (T2D) is a crowded and competitive landscape with multiple “me-too,” generic and biosimilar drugs entering the market, with market growth primarily driven by an increasing prevalent population across nine major markets (9MM: US, France, Germany, Italy, Spain, UK, Japan, China, and India).
Expert insights. Personalized for you.
111 
Let's personalize your content